Skip to content

Maintenance Transcranial Electrical Stimulation for Depression

A Study of Transcranial Electrical Stimulation (TES) as a Maintenance Treatment for Depression

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01890356
Enrollment
25
Registered
2013-07-01
Start date
2013-06-30
Completion date
2018-02-28
Last updated
2018-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder, Major Depressive Disorder

Keywords

Depression, Treatment, Transcranial electrical stimulation, Maintenance

Brief summary

Transcranial electrical stimulation (TES) techniques offer a novel treatment approach for depression and have shown promising efficacy. However, there is no published data to date on their effectiveness as a maintenance treatment. This study will investigate ways of using TES as a maintenance treatment to prevent relapse in depression.

Interventions

DEVICETranscranial electrical stimulation

Sponsors

The University of New South Wales
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All participants will be ≥ 18 years old. * Participants must have experienced a significant clinical response, defined as ≥ 50% decrease from baseline scores on the Montgomery Asberg Depression Rating Scale (MADRS).

Exclusion criteria

* Inadequate response to acute trial of TES. * Suicidality. * Clinically defined neurological disorder or insult. * Metal in the cranium, skull defects, or skin lesions on scalp (cuts, abrasions, rash) at proposed electrode sites. * Pregnancy (women of childbearing age will be asked to undergo a urine pregnancy test prior to starting the study). * Concurrent long acting benzodiazepines, ritalin or dexamphetamine medication. * Treatment for depression is changed during months 3-9 of the trial.

Design outcomes

Primary

MeasureTime frame
Montgomery Asberg Depression Rating Scale for Depression (MADRS)9 months

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026